Shares of Hims & Hers (NYSE:HIMS) fell 15% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no ...

The Food and Drug Administration allows for licensed compounding pharmacies to make copies of certain drugs in short supply, and that has included semaglutide and tirzepatide, the main ingredients in ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical ...

Modern medical innovations continue to transform treatment approaches for chronic conditions, and Ozempic stands at the ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

The company's semaglutide injection—better known by the brand names Ozempic and Wegovy—has become well-known for its weight-loss results and ability to manage diabetes. And while there are several ...

Hims & Hers suffered a deep pullback in August after the FDA removed semaglutide from its shortage list (compound makers can ...

"The nomination of semaglutide to the FDA’s DDC Lists is ... "These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits.

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

Meanwhile, Novo Nordisk, which makes semaglutide, has asked the FDA to add the GLP-1 to a list of drugs too difficult to compound. This would essentially put a stop to pharmacies making copies of ...

Pharmaceuticals announced it will present data from two studies related to LX9851, its investigational compound for obesity and ...